您当前的位置:

Cefazolin (sodium salt).

目录号: PC13033 纯度: ≥98%
广谱的第一代头孢菌素抗生素,Cefazolin钠是第一代头孢类抗生素, 用于治疗多种细菌感染。
CAS No. :27164-46-1
商品编号 规格 价格 会员价 是否有货 数量
PC13033-250mg 250mg ¥728.00 请登录
PC13033-500mg 500mg ¥1142.00 请登录
PC13033-1g 1g ¥1540.00 请登录
PC13033-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥637.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Cefazolin (sodium salt).
中文别名
头孢唑啉钠;唑啉头孢菌素钠;头孢唑啉钠 GMP;头孢唑啉钠盐;Cefazolin Sodium Salt 头孢唑啉钠盐;Cefazolin sodium salt 头孢唑啉钠;WAKO034-22841头孢唑啉钠标准品;头孢唑林钠;头孢唑林钠 标准品;头孢唑林钠盐;头孢唑啉钠 标准品;头孢唑啉钠及其杂质标准品;头孢唑啉钠酸盐标准品;头饱唑啉钠;(6R,7R)-3-[[(5-甲基-1,3,4-噻二唑-2-基)硫]甲基]-7-[(1H-四唑-1-基)乙酰氨基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸钠盐
英文名称
Cefazolin (sodium salt)
英文别名
cefazolin sodium salt;Cefazolin Sodium;Cefazolin;7-epi-Cefazolin Sodium Salt;Cefazolin (sodium salt);Cefazolin Sodium Sterile;ancef;Atirin;Azolin;Cefazil;cephazolin sodium;Cephazolin sodium salt;firmacef;gramaxin;kefzol;Sodium cefazolin;Sodium cephazolin;totacef;zolicef;Sodium (6R-trans)-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-(1H-tetrazol-1-ylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;Cefazoline sodium;Monosodium cefazolin;Cefazolin (sodium);Cefamedin;Biazolina;CEFAZOLIN AND DEXTROSE;Sodium CEZ;Cefalomicina;Cefabiozim;Zolisint;Neofazol;Cefacidal;Lampocef;Zolin;Recef;MLS000028706;Bor-Cefazol;CEZ sodium;Cefazina;Liviclina;P380M0454Z;SMR000058708;Lilly 46083;SKF 41558;ANCEF I
Cas No.
27164-46-1
分子式
C14H13N8NaO4S3
分子量
476.49
包装储存

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

详情描述

广谱的第一代头孢菌素抗生素,Cefazolin钠是第一代头孢类抗生素, 用于治疗多种细菌感染。

生物活性

Cefazolin sodium is a first-generation cephalosporin antibiotic and can be used in varieties of bacterial infections research. Cefazolin sodium has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD).

性状

Solid

IC50 & Target[1][2]

β-lactam

 

体外研究(In Vitro)

Cefazolin sodium (0-300 μg/ml; 6 or 24 h) has a direct anti-inflammatory effect on C8-B4 cells stimulated by lipopolysaccharide.
Cefazolin sodium (0-400 μM; 72 h) treatment inhibits IL-2, IL-4 and IL-15-induced cell proliferation.
Cefazolin sodium (0-400 μM; 30 min) treatment inhibits IL-2, IL-4, IL-15 and IL-21-stimulated JAK3 phosphorylation.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: C8-B4 cells
Concentration: 0, 50, 100, 150, 200, 250, or 300 μg/ml
Incubation Time: 6 or 24 hours
Result: Inhibited the increase of IL-1β at all doses, but inhibited the increase of IL-6 only at 200 μg/ml.

Cell Proliferation Assay

Cell Line: PBMC, and TF-1 cells
Concentration: 0, 100, 200, and 400 μM
Incubation Time: 72 hours
Result: Reduced IL-2, IL-4 and IL-15-induced cell proliferation, suggested that Cefazolin interferes not only with IL-15Rα, but also with IL-2/IL-15Rβ and/or γc.

Cell Viability Assay

Cell Line: PBMC, NK-92, and TF-1 cells
Concentration: 0, 100, 200, and 400 μM
Incubation Time: 30 min
Result: Diminished the phosphorylation of JAK3 in response to the cytokine treatment, concluded suppressing signal transduction by γc receptors.
体内研究(In Vivo)

Cefazolin sodium (Subcutaneous injection; 300-500 mg/kg; once daily; 5 d) treatment improves learning and memory in mice after surgery.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6- to 8-week-old male CD-1 mice underwent clinical exploratory laparotomy
Dosage: 300-500 mg/kg
Administration: Subcutaneous injection; 300-500 mg/kg; once daily; 5 days
Result: Attenuated learning and memory dysfunction induced by the surgery.
运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

ClinicalTrial
参考文献
溶解度数据
体外研究: 

H2O : ≥ 100 mg/mL (209.87 mM)

DMSO : 100 mg/mL (209.87 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0987 mL 10.4934 mL 20.9868 mL
5 mM 0.4197 mL 2.0987 mL 4.1974 mL
10 mM 0.2099 mL 1.0493 mL 2.0987 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: PBS

    Solubility: 100 mg/mL (209.87 mM); Clear solution; Need ultrasonic

  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2